Mirum reports 2023 net product sales of $178.9M (+142% YoY); guides 2024 sales $310-320M

Mirum Pharmaceuticals, Inc.

2023-FY EPS reported -$4.00 revenue$186,374,000

Full-year 2023 total revenue $186.4M, up 142% over 2022; LIVMARLI net sales $141.8M (+89% YoY).
2024 global net product sales guidance of $310M to $320M, reflecting continued growth across approved medicines.
LIVMARLI PFIC PDUFA date on track for March 13, 2024; CHENODAL NDA for CTX planned H1 2024.
Volixibat VISTAS (PSC) and VANTAGE (PBC) interim analyses expected in first half 2024.
Appointed Joanne Quan, M.D. as Chief Medical Officer; cash and equivalents $286.3M as of Dec 31, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mirum Pharmaceuticals, Inc. updated its the quarter and year ended December 31, 2023 guidance (raised).

Period: the quarter and year ended December 31, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On February 28, 2024, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001759425-24-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.